Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Entrega Inc. is a biotech startup that operates as a program of PureTech Health, headquartered in Boston, Massachusetts. The company focuses on the oral delivery of biologics, vaccines, and other drugs, utilizing proprietary customizable hydrogel dosage forms. These dosage forms create localized fluid microenvironments in the gastrointestinal tract, enabling the effective delivery of large-molecule drugs that are typically administered intravenously.
Founded as part of PureTech Health's initiatives, Entrega has developed its technology under the guidance of Dr. Samir Mitragotri, a prominent figure in drug delivery systems. The scientific advisory board is chaired by Dr. Robert Langer, a renowned professor at MIT, further enhancing the company's credibility and expertise in the field. Entrega has received a strategic investment of $5 million from Eli Lilly to advance its oral delivery technology, marking a significant milestone in its development.
Entrega Inc. specializes in innovative drug delivery systems, particularly for therapeutic peptides. The company aims to revolutionize the administration of biologics through its advanced oral delivery technology, which has shown promise in preclinical studies. Their proprietary hydrogel dosage forms are designed to create localized fluid microenvironments in the gastrointestinal tract, facilitating the delivery of large-molecule drugs that are typically administered intravenously.
The focus on oral delivery systems positions Entrega at the forefront of a critical area in biotechnology, addressing the challenges associated with traditional drug administration methods. The company is particularly interested in therapeutic peptides, which have significant potential in treating various medical conditions. By leveraging its unique technology, Entrega seeks to improve patient compliance and outcomes through more effective drug delivery methods.
Dr. Samir Mitragotri - Co-founder and technology developer. He is known for his work in drug delivery systems and has a background at UC Santa Barbara and the Harvard Wyss Institute.
Dr. Robert Langer - Chair of the Scientific Advisory Board. He is a David H. Koch Institute Professor at MIT and is recognized for his contributions to biomedical engineering and drug delivery.
In December 2017, Entrega Inc. secured a strategic investment of $5 million from Eli Lilly to advance its oral delivery technology for therapeutic peptides. This funding is a significant milestone for the company, indicating confidence in its innovative approach to drug delivery.
As of the latest updates, there have been no new announcements or public activities reported on their website, which limits insights into ongoing projects or developments.
What are Entrega Inc.'s investment criteria?
As a biotech startup, Entrega Inc. does not have traditional investment criteria like a venture capital firm. Instead, it focuses on developing its proprietary technology for oral drug delivery systems, particularly for biologics and therapeutic peptides.
How can I pitch to Entrega Inc.?
Currently, there is no publicly available information regarding a formal pitch process for Entrega Inc. As a startup, it is advisable to reach out through professional networks or connections within PureTech Health to explore potential collaboration opportunities.
What makes Entrega Inc. different from other biotech firms?
Entrega Inc. differentiates itself through its proprietary hydrogel technology that enables the oral delivery of large-molecule drugs, a significant advancement over traditional intravenous methods. This innovative approach aims to enhance patient compliance and therapeutic efficacy.
What is the geographic scope of Entrega Inc.'s operations?
Entrega Inc. is based in Boston, Massachusetts, and primarily focuses on the U.S. market for its drug delivery innovations. However, the potential applications of its technology could extend globally as it develops further.
What is the funding size and check size for Entrega Inc.?
Entrega Inc. has secured a total of $5 million in funding from Eli Lilly. This investment is aimed at advancing its oral delivery technology, although specific check sizes for future funding rounds are not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.